Recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) attenuates caerulein-induced chronic pancreatitis in mice

Biomedicine and Pharmacotherapy

Volumn 66, Issue 2, 2012, Pages 83-88

  Shen, Jiaqing ^a   Gao, Jing ^b   Zhang, Jing ^c   Xiang, Di ^d   Wang, Xia ^b   Qian, Lan ^b   Shen, Jie ^e   Yang, Lijuan ^a   Zhu, Shunying ^b   Wu, Mingyuan ^b   Yu, Yan ^b   Han, Wei ^b   Wang, Xingpeng ^a,e  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c Central Research Institute   (China)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

^e TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Caerulein; Chronic pancreatitis; Mice; Recombinant human interleukin 1 receptor antagonist

Indexed keywords

AMYLASE; CERULETIDE; COLLAGEN; HYDROXYPROLINE; INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRIACYLGLYCEROL LIPASE;

AMYLASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC PANCREATITIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE SEVERITY; EDEMA; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE INJURY; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; WEIGHT REDUCTION;

AMYLASES; ANIMALS; CAERULEIN; COLLAGEN; DISEASE MODELS, ANIMAL; FIBROSIS; HUMANS; HYDROXYPROLINE; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; LIPASE; MALE; MICE; MICE, INBRED C57BL; PANCREATITIS, CHRONIC;

EID: 84862826694     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.11.017     Document Type: Article

References (22)

1. Apte M.V., Pirola R.C., Wilson J.S. Mechanisms of alcoholic pancreatitis. J Gastroenterol Hepatol 2010, 25:1816-1826.
2. Clain J.E., Pearson R.K. Diagnosis of chronic pancreatitis: Is a gold standard necessary?. Surg Clin North Am 1999, 79:829-845.
3. Dimagno M.J., Dimagno E.P. Chronic pancreatitis. Curr Opin Gastroenterol 2011, 27:452-459.
4. Khalid A., Whitcomb D.C. Conservative management of chronic pancreatitis. Eur J Gastroenterol Hepatol 2002, 14:943-949.
5. Laugier R., Grandval P. Interventional treatment of chronic pancreatitis. Eur J Gastroenterol Hepatol 2002, 14:951-955.
6. Braganza J.M., Lee S.H., McCloy R.F., McMahon M.J. Chronic pancreatitis. Lancet 2011, 7:1184-1197.
7. Nagashio Y., Ueno H., Imamura M., Asaumi H., Watanabe S., Yamaguchi T., et al. Inhibition of transforming growth factor beta decreases pancreatic fibrosis and protects the pancreas against chronic injury in mice. Lab Invest 2004, 84:1610-1618.
8. Demols A., Van Laethem J.L., Quertinmont E., Degraef C., Delhaye M., Geerts A., et al. Endogenous interleukin-10 modulates fibrosis and regeneration in experimental chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol 2002, 282:1105-1112.
9. Norman J., Fink G., Franz M., Guffey J., Carter G., Davison B., et al. Active interleukin-1 receptor required for maximal progression of acute pancreatitis. Ann Surg 1996, 223:163-169.
10. Norman J., Franz M., Messina J., Riker A., Fabri P.J., Rosemurgy A.S., et al. Interleukin-1 receptor antagonist decreases severity of experimental acute pancreatitis. Surgery 1995, 117:648-655.
11. Norman J., Franz M., Fink G., Messina J., Fabri P.J., Gower W., et al. Decreased mortality of severe acute pancreatitis after proximal cytokine blockade. Ann Surg 1995, 221:625-631.
12. Tanaka N., Murata A., Uda K., Toda H., Kato T., Hayashida H., et al. Interleukin-1 receptor antagonist modifies the changes in vital organs induced by acute necrotizing pancreatitis in a rat experimental model. Crit Care Med 1995, 23:901-908.
13. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550.
14. Hu J., Yan D., Gao J., Xu C., Yuan Y., Zhu R., et al. rhIL-1Ra reduces hepatocellular apoptosis in mice with acetaminophen-induced acute liver failure. Lab Invest 2010, 90:1737-1746.
15. Marrache F., Tu S.P., Bhagat G., Pendyala S., Osterreicher C.H., Gordon S., et al. Overexpression of interleukin-1beta in the murine pancreas results in chronic pancreatitis. Gastroenterology 2008, 135:1277-1287.
16. Neuschwander-Tetri B.A., Burton F.R., Presti M.E., Britton R.S., Janney C.G., Garvin P.R., et al. Repetitive self-limited acute pancreatitis induces pancreatic fibrogenesis in the mouse. Dig Dis Sci 2000, 45:665-674.
17. Gabellec M.M., Griffais R., Fillion G., Haour F. Analysis of brain mRNA by reverse transcription-polymerase chain reaction and hybridization with digoxigeninlabeled DNA probe. Brain Res 1997, 2:145-151.
18. van Westerloo D.J., Florquin S., de Boer A.M., Daalhuisen J., de Vos A.F., Bruno M.J., et al. Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice. Am J Pathol 2005, 166:721-728.
19. Zhang J., Xiang D., Zhu S., Mao W., Lu H., Wu M., et al. Interleukin-1 receptor antagonist inhibits normal hematopoiesis and reduces lethality and bone marrow toxicity of 5-fluouracil in mouse. Biomed Pharmacother 2008, 63:501-508.
20. Fink G., Yang J., Carter G., Norman J. Acute pancreatitis-induced enzyme release and necrosis are attenuated by IL-1 antagonism through an indirect mechanism. J Surg Res 1997, 67:94-97.
21. Mancini R., Benedetti A., Jezequel A.M. An interleukin-1 receptor antagonist decreases fibrosis induced by dimethylnitrosamine in rat liver. Virchows Arch 1994, 424:25-31.
22. Ortiz L.A., Dutreil M., Fattman C., Pandey A.C., Torres G., Go K., et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 2006, 104:11002-11007.